Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|September 15, 2014
- BioPharm International-09-15-2014
- Volume 2014 eBook
- Issue 3
Biopharma Contract Manufacturing Prices Go Up—and Down
Author(s)William Downey
A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.
Advertisement
A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.
from BioPharm International’s 2014 Outsourcing Strategies eBook.
Articles in this issue
about 12 years ago
Ensuring Sound Bioanalytical Methods Transferabout 12 years ago
CMOs Gear Up for Biologics Manufacturing Challengesabout 12 years ago
Weighing Clinical Trial Outsourcing Optionsabout 12 years ago
Outsourcing Trends in Biopharmaceutical ManufacturingAdvertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
4
FDA Grants RMAT and Fast Track Designations to AbelZeta’s Bispecific CAR-T Prizlon-cel in Large B-Cell Lymphoma
5